Table 2.
Baseline characteristics of individuals stratified by the presence or absence of LVHa
| LVH (N = 278) | No LVH (N = 369) | P-value | |
| Age (years) | 67.6 ± 10.3 | 68.3 ± 10.6 | 0.4 |
| Race (Black) | 86 (31) | 61 (17) | <0.001 |
| BMI (kg/m2) | 29.2 ± 5.9 | 29.2 ± 5.9 | 0.9 |
| Active smoking | 79 (30) | 81 (23) | 0.045 |
| SBP (mmHg) | 149.3 ± 27.0 | 145.4 ± 25.5 | 0.09 |
| DBP (mmHg) | 71.1 ± 16.5 | 70.2 ± 15.3 | 0.5 |
| Charlson comorbidity index | 2.6 ± 1.7 | 2.6 ± 1.7 | 0.8 |
| DM | 166 (60) | 229 (62) | 0.5 |
| CAD | 130 (47) | 203 (56) | 0.033 |
| CVA | 44 (16) | 51 (14) | 0.5 |
| PVD | 70 (25) | 103 (28) | 0.4 |
| EF | 46 ± 12 | 51 ± 10 | <0.001 |
| Hyperlipidemia | 129 (47) | 190 (52) | 0.2 |
| Malignancy | 46 (17) | 72 (20) | 0.3 |
| Liver disease | 15 (5) | 20 (5) | 0.9 |
| Pulmonary disease | 62 (22) | 89 (24) | 0.6 |
| eGFR (mL/min/1.73m2) | 34.9 ± 19.9 | 38.4 ± 21.3 | 0.03 |
| Serum albumin (g/dL) | 3.4 ± 0.6 | 3.5 ± 0.7 | 0.7 |
| Serum cholesterol (mg/dL) | 186.3 ± 55.1 | 181.0 ± 52.4 | 0.2 |
| Serum calcium (mg/dL) | 9.1 ± 0.6 | 9.0 ± 0.7 | 0.12 |
| Serum phosphorus (mg/dL) | 4.0 ± 1.0 | 3.8 ± 1.1 | 0.03 |
| Blood Hgb (g/dL) | 12.0 ± 2.1 | 12.3 ± 2.1 | 0.14 |
| Blood WBC (1000/mm3) | 8.2 ± 3.43 | 8.3 ± 4.2 | 0.6 |
| Blood lymphocytes (% WBC) | 22.4 ± 13.9 | 21.2 ± 16 | 0.3 |
| Bicarbonate (mmol/L) | 25.9 ± 4.2 | 25.6 ± 4.0 | 0.4 |
| Proteinuria (mg/24 h) | 1054 (885–1256) | 804 (684–946) | 0.027 |
| Statin use | 123 (44) | 174 (47) | 0.5 |
| ACEI/ARB use | 178 (64) | 234 (63) | 0.8 |
| ASA use | 141 (51) | 191 (53) | 0.7 |
| Beta blocker use | 145 (52) | 191 (52) | 0.9 |
a
Data are presented as means ± SD, number (% of total) or geometric means (95% CI). BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; DM, diabetes mellitus; CVA, cerebrovascular accident; PVD, peripheral vascular disease; eGFR, estimated GFR; Hgb, haemoglobin; ASA, amino salicylic acid. Comparisons were made by t-test or chi-square test.